Launch Long-Term Subscriptions for Wegovy Medications to Combat Obesity
Novo Nordisk has announced the launch of long-term subscriptions for Wegovy medications aimed at combating obesity, offering users savings of up to <strong>$1,200 annually</strong> on injections and <strong>$600 annually</strong> on pills. This initiative is part of the company's strategy to compete with Eli Lilly.